Ocuphire Pharma Inc OCUP

Healthcare

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

NDAQ:OCUP - Post by User

Ocuphire Pharma Inc > FDA PDUFA Date September 28, 2023

<< Previous

Bullboard Posts

Comment by joebravoon Sep 27, 2023 8:25am

63 Views

Post# 35656379

RE:FDA PDUFA Date September 28, 2023

And there you have it. FDA Approval of Nyxol RM, which will be manufactured and sold under the name RYZUMVI by Viatris starting first half of 2024.

Ocuphire will now receive their first milestone payment of $10 million from Viatris, with more to follow on success of their other applications for the drops, as well as a double digit royalty on "Net Sales" with Zero Cost to Ocuphire.

<< Previous

Bullboard Posts

This profitable gold stock is on its way up